BioMarin Pharmaceutical

person throwing away garbage or recycling
Biotech

After $4.8B Amicus buy, BioMarin drops genetic disease asset

As recently as October, BioMarin said it was planning to launch a phase 2 study for the asset in the first half of 2026.
Gabrielle Masson Dec 22, 2025 11:12am
women leadership executive female woman

Sanofi snags BioMarin leader to serve as CMO

Aug 26, 2025 11:06am
pipeline pipes RD research

BioMarin drops PKU drug once seen as possible Palynziq successor

Aug 5, 2025 4:48am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect

May 16, 2025 8:46am
Graphic image of a pen signing a signature while two strangelooking business people cheer

Spruce inks deal for BioMarin asset, plans 2026 approval filing

Apr 15, 2025 10:29am
Motion blurs of people hurrying around an office

BioMarin's R&D head hopes pipeline of good ideas won't 'dry out'

Feb 21, 2025 7:00am